Abbrea Capital LLC Has $5.50 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Abbrea Capital LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,426 shares of the company’s stock after acquiring an additional 383 shares during the period. Abbrea Capital LLC’s holdings in Eli Lilly and Company were worth $5,495,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of LLY. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $27,000. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $36,000. Finally, Family CFO Inc bought a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now directly owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

LLY traded up $8.64 during midday trading on Friday, hitting $733.51. 1,998,801 shares of the company were exchanged, compared to its average volume of 3,021,262. The company’s 50 day simple moving average is $762.75 and its 200 day simple moving average is $664.94. The firm has a market capitalization of $696.95 billion, a price-to-earnings ratio of 126.80, a price-to-earnings-growth ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 1-year low of $380.77 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period last year, the firm earned $2.09 EPS. The company’s quarterly revenue was up 28.1% on a year-over-year basis. As a group, sell-side analysts predict that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Morgan Stanley upped their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Monday, April 15th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. Finally, JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.